Bayer AG (ETR: BAYN) announced that China’s National Medical Products Administration (NMPA) has approved Sunharbo (asundexian tablets), the world’s first (first‑in‑class) activated Factor XI (FXIa) inhibitor, for reducing the risk of stroke in adult patients after an ischemic stroke or high‑risk transient ischemic attack (TIA), excluding patients with cardioembolic stroke. The approval makes China among the first countries globally to authorize the drug.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval with Priority Review designation |
| Product | Sunharbo (asundexian tablets) |
| Class | First‑in‑class activated Factor XI (FXIa) inhibitor |
| Indication | Reduction of stroke risk in adults after ischemic stroke or high‑risk TIA, excluding cardioembolic stroke |
| Review Timeline | Approval granted approximately half a year from acceptance of the marketing application |
| Pivotal Evidence | Global Phase III OCEANIC‑STROKE study |
| Global Position | China among the first countries worldwide to approve |
Drug Profile & Mechanism of Action
- Molecule: Asundexian, an oral, first‑in‑class small‑molecule inhibitor of activated Factor XI (FXIa).
- Target Biology: FXIa sits at a key juncture of the intrinsic coagulation pathway, primarily participating in the formation and amplification of pathological thrombi while having a relatively limited impact on normal physiological hemostasis.
- Innovation: By selectively inhibiting FXIa, asundexian is designed to overcome the long‑standing clinical dilemma of intensified antithrombotic therapy – where “greater efficacy is often accompanied by increased bleeding” – offering a potential decoupling of antithrombotic benefit from bleeding risk.
- Treatment Position: Intended to provide additional protection on top of existing antiplatelet therapy for secondary stroke prevention.
- Origin: Developed by Bayer; advanced through the global OCEANIC clinical program.
Clinical Evidence – Phase III OCEANIC‑STROKE Study
| Endpoint | Result (Asundexian) | Comparator | Relative Benefit |
|---|---|---|---|
| Ischemic Stroke Risk (Global Population) | Significant risk reduction | Placebo | −26 % |
| Recurrent Ischemic Stroke Risk (Chinese Population) | HR 0.68 (95 % CI 0.48–0.96) | Placebo | −32 % – numerically greater than the global population |
| Major Bleeding (ISTH Definition) | No increased risk | Placebo | Favorable efficacy–safety profile |
| Study Size / Duration | Not disclosed in the announcement | – | – |
OCEANIC‑STROKE is the first successfully completed FXIa inhibitor Phase III stroke study to yield positive results, validating the FXIa class in secondary stroke prevention. Subgroup data from the Chinese population showed a numerically greater risk reduction than that observed globally, supporting the relevance of asundexian for Chinese patients.
Market Impact & Outlook
- China Regulatory First‑Mover: With Priority Review status and an approval roughly half a year from acceptance, China joins the first wave of global markets for Sunharbo – underscoring both NMPA’s accelerated pathway for innovative drugs and Bayer’s China‑first launch strategy.
- Stroke Prevention Landscape: Secondary prevention after ischemic stroke and high‑risk TIA has long relied on antiplatelet regimens constrained by the efficacy‑versus‑bleeding trade‑off; asundexian introduces a new mechanism of action as add‑on therapy for a large, high‑recurrence‑risk population.
- First‑in‑Class Validation: The positive OCEANIC‑STROKE result marks a watershed for the FXIa inhibitor field, reviving momentum for a class that had faced setbacks in other indications and positioning asundexian as its first approved representative.
- Franchise Expansion for Bayer: Sunharbo strengthens Bayer’s established cardiovascular portfolio and adds a differentiated, orally administered asset with the potential to become a new standard of care in post‑stroke prevention.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the commercialization of Sunharbo (asundexian) in China and globally, including market adoption, reimbursement and guideline incorporation, further regulatory filings, and clinical development. Actual results may differ materially due to risks including competitive therapies, pricing and access dynamics, real‑world safety experience, and evolving standards of care.-Fineline Info & Tech
